Related Experiment Video
Updated: May 17, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Novel antiinflammatory therapies for COPD
1Pulmonary Division, Department of Medicine, St. Francis Hospital, Hartford, CT; Stritch-Loyola School of Medicine, Chicago, IL.
Chest
|November 8, 2012
Summary
Understanding chronic obstructive pulmonary disease (COPD) inflammation is crucial. This review covers existing and novel anti-inflammatory agents, including approved drugs and new molecular entities, for COPD treatment.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Inflammation Research
Background:
- The precise biological mechanisms driving chronic obstructive pulmonary disease (COPD) inflammation remain incompletely understood.
- Targeting inflammation in COPD represents a significant unmet medical need for effective therapeutic strategies.
Purpose of the Study:
- To review current and emerging anti-inflammatory agents with potential therapeutic applications in COPD management.
- To categorize these agents based on their development stage and therapeutic targets.
Main Methods:
- Literature review of approved and investigational anti-inflammatory drugs for COPD.
- Categorization of agents into those repurposed from other indications and novel molecular entities developed specifically for COPD.
Main Results:
- Several drug classes approved for other conditions, such as statins, phosphodiesterase inhibitors, long-acting beta-agonists, tiotropium bromide, rosiglitazone, and monoclonal antibodies, show potential for COPD anti-inflammatory effects.
- New molecular entities under development include chemokine receptor antagonists, matrix metalloproteinase inhibitors, p38 MAPK inhibitors, and stem cell therapies.
Conclusions:
- A diverse range of anti-inflammatory agents, from repurposed drugs to novel targeted therapies, are in development for COPD.
- Further research and clinical trials are essential to validate the efficacy and safety of these agents in treating COPD inflammation.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...